MLTX MoonLake Immunotherapeutics

Nasdaq moonlaketx.com


$ 9.12 $ 0.00 (0 %)    

Friday, 17-Oct-2025 15:31:22 EDT
QQQ $ 604.38 $ 6.77 (1.13 %)
DIA $ 462.39 $ 3.03 (0.66 %)
SPY $ 664.66 $ 5.19 (0.79 %)
TLT $ 91.15 $ -0.08 (-0.09 %)
GLD $ 388.76 $ -8.38 (-2.11 %)
$ 9.38
$ 9.05
$ 9.11 x 317
$ 9.13 x 74
$ 8.81 - $ 9.25
$ 5.95 - $ 62.75
4,590,576
na
602.48M
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-20-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 02-17-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-21-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 12-03-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-moonlake-to-neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades MoonLake (NASDAQ:MLTX) from Buy to Neutral.

 guggenheim-maintains-buy-on-moonlake-lowers-price-target-to-20

Guggenheim analyst Yatin Suneja maintains MoonLake (NASDAQ:MLTX) with a Buy and lowers the price target from $80 to $20.

 wedbush-maintains-outperform-on-moonlake-lowers-price-target-to-18

Wedbush analyst Yun Zhong maintains MoonLake (NASDAQ:MLTX) with a Outperform and lowers the price target from $80 to $18.

 citigroup-downgrades-moonlake-to-neutral-lowers-price-target-to-5

Citigroup analyst Samantha Semenkow downgrades MoonLake (NASDAQ:MLTX) from Buy to Neutral and lowers the price target from $...

 needham-maintains-buy-on-moonlake-lowers-price-target-to-20

Needham analyst Serge Belanger maintains MoonLake (NASDAQ:MLTX) with a Buy and lowers the price target from $66 to $20.

 wolfspeed-tilray-robinhood-etsy-and-moonlake-immunotherapeutics-why-these-5-stocks-are-on-investors-radars-today-corrected

U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to c...

 crude-oil-falls-sharply-carnival-posts-upbeat-earnings

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded do...

Core News & Articles

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...

 nasdaq-jumps-150-points-us-pending-home-sales-rise

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market ...

 rbc-capital-downgrades-moonlake-to-sector-perform-lowers-price-target-to-10

RBC Capital analyst Brian Abrahams downgrades MoonLake (NASDAQ: MLTX) from Outperform to Sector Perform and lowers the price...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 inventiva-moonlake-immunotherapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiv...

 this-electronic-arts-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 btig-downgrades-moonlake-to-neutral-maintains-price-target-to-85

BTIG analyst Julian Harrison downgrades MoonLake (NASDAQ: MLTX) from Buy to Neutral and maintains the price target from $85 ...

 why-merus-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...

 reported-sunday-moonlake-phase-3-vela-trials-show-sonelokimab-achieves-statistically-significant-hiscr75-responses-in-moderate-to-severe-hidradenitis-suppurativa

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with modera...

 goldman-sachs-maintains-buy-on-moonlake-raises-price-target-to-82

Goldman Sachs analyst Richard Law maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price target from $74 to $82.

 moonlake-q2-2025-eps-087-misses-072-estimate

Ended the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION